[go: up one dir, main page]

AR044050A1 - Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos - Google Patents

Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos

Info

Publication number
AR044050A1
AR044050A1 ARP040101354A ARP040101354A AR044050A1 AR 044050 A1 AR044050 A1 AR 044050A1 AR P040101354 A ARP040101354 A AR P040101354A AR P040101354 A ARP040101354 A AR P040101354A AR 044050 A1 AR044050 A1 AR 044050A1
Authority
AR
Argentina
Prior art keywords
treatment
ivermectine
dermatological disorders
ivermectin
topical
Prior art date
Application number
ARP040101354A
Other languages
English (en)
Inventor
Vincent Manetta
Gary R Watkins
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33104376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of AR044050A1 publication Critical patent/AR044050A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilización de ivermectina para la fabricación de una composición farmacéutica tópica destinada al tratamiento de la rosácea. Reivindicación 15: Composición tópica destinada al uso humano caracterizada porque es una emulsión que comprende: a) una fase aceitosa que comprende cuerpos grasos; b) al menos un emulsionante tensioactivo; c) ivermectina; d) un o varios solvente y/o propenetrante del activo; e) y agua. Reivindicación 20: Utilización de la composición de acuerdo con cualquiera de las reivindicaciones 15 a 19, para la preparación de un medicamento destinado al tratamiento de las afecciones dermatológicas.
ARP040101354A 2003-04-24 2004-04-22 Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos AR044050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques

Publications (1)

Publication Number Publication Date
AR044050A1 true AR044050A1 (es) 2005-08-24

Family

ID=33104376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101354A AR044050A1 (es) 2003-04-24 2004-04-22 Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos

Country Status (11)

Country Link
US (6) US8815816B2 (es)
KR (1) KR101291824B1 (es)
CN (2) CN1777433A (es)
AR (1) AR044050A1 (es)
AT (1) ATE516037T1 (es)
DK (1) DK1620113T3 (es)
ES (1) ES2371945T3 (es)
FR (1) FR2854074B1 (es)
PT (1) PT1620113E (es)
SI (1) SI1620113T1 (es)
ZA (1) ZA200507346B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
WO2008067054A2 (en) 2006-10-12 2008-06-05 Topaz Pharmaceuticals Llc Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
US7953614B1 (en) 2006-11-22 2011-05-31 Dr Systems, Inc. Smart placement rules
CN102231948B (zh) * 2008-10-29 2015-08-19 托帕茨医药股份有限公司 用于乳液类治疗用局部配制剂的防腐剂系统
CN102784166B (zh) * 2012-08-01 2015-11-25 青岛绿曼生物工程有限公司 治疗家畜螨虫病的复方伊维菌素组合物及其制备方法
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
JP6448641B2 (ja) 2013-11-29 2019-01-09 ガルデルマ・ソシエテ・アノニム アトピー性皮膚炎の治療及び／又は予防のためのアベルメクチンファミリー又はミルベマイシンファミリーの化合物
RU2016141961A (ru) 2014-03-28 2018-04-28 Галдерма Ресерч Энд Девелопмент Несмываемая химическая пена, содержащая пероксид бензоила
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN104127334A (zh) * 2014-08-19 2014-11-05 杨人源 一种杀菌除螨宠物香波
EP3220903A1 (fr) * 2014-11-20 2017-09-27 Galderma S.A. Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne
FR3041537B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041540B1 (fr) * 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.
FR3041539B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041538B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041541B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
JP6901472B2 (ja) * 2015-10-13 2021-07-14 ガルデルマ エス．エー． １種又は複数のアベルメクチンを含む安定したエマルションを調製する方法
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
TR201714097A2 (tr) * 2017-09-22 2018-10-22 Assos Ilac Kimya Gida Ueruenleri Ueretim Ve Ticaret Anonim Sirketi İvermekti̇n topi̇k formülasyon
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019136211A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating autoimmune disorders with ivermectin
WO2019152560A1 (en) * 2018-01-31 2019-08-08 Bio33 Degrees, Inc. Compositions and methods for topical treatment of dermal and ocular conditions
CN108272750A (zh) * 2018-04-25 2018-07-13 菏泽学院 一种治疗动物皮肤疥癣病的软膏剂及其制备方法
JP7525406B2 (ja) 2018-06-15 2024-07-30 ダブリュー・アール・グレース・アンド・カンパニー－コーン 消泡剤活性物質、その製造方法、及び消泡配合物
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2021247283A1 (en) * 2020-06-04 2021-12-09 Amcyte Pharma, Inc. Delivery of aerosolized micromolar composition concentrations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
FR2725369B1 (fr) * 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
KR100277287B1 (ko) 1995-09-25 2001-01-15 맨슨 하비 콜린 거대환 락톤 구충제 조성물
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6521237B2 (en) * 1998-11-12 2003-02-18 Johnson & Johnson Consumer Companies, Inc. Skin care composition
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
CA2473760C (en) 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
AU2003225651A1 (en) 2002-03-04 2003-09-22 Divergence, Inc. Nematicidal fatty acid and fatty acid ester related compounds
BRPI0410503B8 (pt) 2003-04-24 2021-05-25 Galderma Sa composição tópica e uso da composição
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme

Also Published As

Publication number Publication date
US20150306124A1 (en) 2015-10-29
US20140336139A1 (en) 2014-11-13
US20140051653A1 (en) 2014-02-20
CN103800353A (zh) 2014-05-21
FR2854074B1 (fr) 2007-11-23
SI1620113T1 (sl) 2011-10-28
US11033565B2 (en) 2021-06-15
CN1777433A (zh) 2006-05-24
ATE516037T1 (de) 2011-07-15
KR101291824B1 (ko) 2013-07-31
ZA200507346B (en) 2006-08-30
FR2854074A1 (fr) 2004-10-29
PT1620113E (pt) 2011-09-12
US20150306027A1 (en) 2015-10-29
US8815816B2 (en) 2014-08-26
US20170281663A1 (en) 2017-10-05
KR20120062028A (ko) 2012-06-13
ES2371945T3 (es) 2012-01-11
DK1620113T3 (da) 2011-09-12
US20170281664A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
MX2020012595A (es) Composiciones farmaceuticas topicas.
AR035131A1 (es) Composiciones topicas y metodos para el tratamiento del dolor
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
RU2350333C3 (ru) Применение ивермектина для лечения дерматологических расстройств
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
DE69940015D1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
AR054300A1 (es) Aparato y sistema de microproyeccion con escaso potencial infeccioso
AR033688A1 (es) Composicion parenteral reconstituible
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR109263A2 (es) Composición que comprende moxidectina
EE200200500A (et) Uus iseemulgeeruv ravimi manustamise süsteem
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
DK1267831T3 (da) Hidtil ukendt selvemulgerende system til lægemiddelindgift
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ATE427737T1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
SE0102993D0 (sv) New self emulsifying drug delivery system
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio

Legal Events

Date Code Title Description
FC Refusal